Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Clinical actionability of molecular targets in endometrial cancer.

Urick ME, Bell DW.

Nat Rev Cancer. 2019 Sep;19(9):510-521. doi: 10.1038/s41568-019-0177-x. Epub 2019 Aug 6. Review.

PMID:
31388127
2.

Molecular Genetics of Endometrial Carcinoma.

Bell DW, Ellenson LH.

Annu Rev Pathol. 2019 Jan 24;14:339-367. doi: 10.1146/annurev-pathol-020117-043609. Epub 2018 Oct 17.

PMID:
30332563
3.

In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib.

Urick ME, Bell DW.

Mol Carcinog. 2018 Nov;57(11):1445-1457. doi: 10.1002/mc.22867. Epub 2018 Jul 12.

PMID:
29963728
4.

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials.

MacKay HJ, Levine DA, Bae-Jump VL, Bell DW, McAlpine JN, Santin A, Fleming GF, Mutch DG, Nephew KP, Wentzensen N, Goodfellow PJ, Dorigo O, Nijman HW, Broaddus R, Kohn EC.

Oncotarget. 2017 Aug 3;8(48):84579-84594. doi: 10.18632/oncotarget.19961. eCollection 2017 Oct 13. Review.

5.

The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.

Le Gallo M, Rudd ML, Urick ME, Hansen NF; National Institutes of Health Intramural Sequencing Center Comparative Sequencing Program, Merino MJ, Mutch DG, Goodfellow PJ, Mullikin JC, Bell DW.

Cancer. 2018 Jan 1;124(1):65-73. doi: 10.1002/cncr.30971. Epub 2017 Sep 21.

6.

Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing.

Le Gallo M, Rudd ML, Urick ME, Hansen NF, Zhang S; NISC Comparative Sequencing Program, Lozy F, Sgroi DC, Vidal Bel A, Matias-Guiu X, Broaddus RR, Lu KH, Levine DA, Mutch DG, Goodfellow PJ, Salvesen HB, Mullikin JC, Bell DW.

Cancer. 2017 Sep 1;123(17):3261-3268. doi: 10.1002/cncr.30745. Epub 2017 May 9.

7.

Next-Generation Sequencing.

Le Gallo M, Lozy F, Bell DW.

Adv Exp Med Biol. 2017;943:119-148. Review.

PMID:
27910067
8.

Epidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences.

Felix AS, Yang HP, Bell DW, Sherman ME.

Adv Exp Med Biol. 2017;943:3-46. Review.

PMID:
27910063
9.

Robust Detection of DNA Hypermethylation of ZNF154 as a Pan-Cancer Locus with in Silico Modeling for Blood-Based Diagnostic Development.

Margolin G, Petrykowska HM, Jameel N, Bell DW, Young AC, Elnitski L.

J Mol Diagn. 2016 Mar;18(2):283-98. doi: 10.1016/j.jmoldx.2015.11.004. Epub 2016 Feb 5.

10.

Influence of growth rate on the physiological response of marine Synechococcus to phosphate limitation.

Kretz CB, Bell DW, Lomas DA, Lomas MW, Martiny AC.

Front Microbiol. 2015 Feb 11;6:85. doi: 10.3389/fmicb.2015.00085. eCollection 2015.

11.

The mutational landscape of endometrial cancer.

Hong B, Le Gallo M, Bell DW.

Curr Opin Genet Dev. 2015 Feb;30:25-31. doi: 10.1016/j.gde.2014.12.004. Epub 2015 Jan 23. Review.

12.

Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.

Rudd ML, Mohamed H, Price JC, O'Hara AJ, Le Gallo M, Urick ME; NISC Comparative Sequencing Program, Cruz P, Zhang S, Hansen NF, Godwin AK, Sgroi DC, Wolfsberg TG, Mullikin JC, Merino MJ, Bell DW.

BMC Cancer. 2014 Nov 26;14:884. doi: 10.1186/1471-2407-14-884.

13.

Novel genetic targets in endometrial cancer.

Bell DW.

Expert Opin Ther Targets. 2014 Jul;18(7):725-30. doi: 10.1517/14728222.2014.909414. Epub 2014 Apr 21.

14.

The emerging genomic landscape of endometrial cancer.

Le Gallo M, Bell DW.

Clin Chem. 2014 Jan;60(1):98-110. doi: 10.1373/clinchem.2013.205740. Epub 2013 Oct 29. Review.

15.

Recurrent patterns of DNA methylation in the ZNF154, CASP8, and VHL promoters across a wide spectrum of human solid epithelial tumors and cancer cell lines.

Sánchez-Vega F, Gotea V, Petrykowska HM, Margolin G, Krivak TC, DeLoia JA, Bell DW, Elnitski L.

Epigenetics. 2013 Dec;8(12):1355-72. doi: 10.4161/epi.26701. Epub 2013 Oct 22.

16.

Sequencing of candidate chromosome instability genes in endometrial cancers reveals somatic mutations in ESCO1, CHTF18, and MRE11A.

Price JC, Pollock LM, Rudd ML, Fogoros SK, Mohamed H, Hanigan CL, Le Gallo M; NIH Intramural Sequencing Center (NISC) Comparative Sequencing Program, Zhang S, Cruz P, Cherukuri PF, Hansen NF, McManus KJ, Godwin AK, Sgroi DC, Mullikin JC, Merino MJ, Hieter P, Bell DW.

PLoS One. 2013 Jun 3;8(6):e63313. doi: 10.1371/journal.pone.0063313. Print 2014.

17.

Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.

Le Gallo M, O'Hara AJ, Rudd ML, Urick ME, Hansen NF, O'Neil NJ, Price JC, Zhang S, England BM, Godwin AK, Sgroi DC; NIH Intramural Sequencing Center (NISC) Comparative Sequencing Program, Hieter P, Mullikin JC, Merino MJ, Bell DW.

Nat Genet. 2012 Dec;44(12):1310-5. doi: 10.1038/ng.2455. Epub 2012 Oct 28.

18.

The genomics and genetics of endometrial cancer.

O'Hara AJ, Bell DW.

Adv Genomics Genet. 2012 Mar;2012(2):33-47.

19.

Predisposition to cancer caused by genetic and functional defects of mammalian Atad5.

Bell DW, Sikdar N, Lee KY, Price JC, Chatterjee R, Park HD, Fox J, Ishiai M, Rudd ML, Pollock LM, Fogoros SK, Mohamed H, Hanigan CL; NISC Comparative Sequencing Program, Zhang S, Cruz P, Renaud G, Hansen NF, Cherukuri PF, Borate B, McManus KJ, Stoepel J, Sipahimalani P, Godwin AK, Sgroi DC, Merino MJ, Elliot G, Elkahloun A, Vinson C, Takata M, Mullikin JC, Wolfsberg TG, Hieter P, Lim DS, Myung K.

PLoS Genet. 2011 Aug;7(8):e1002245. doi: 10.1371/journal.pgen.1002245. Epub 2011 Aug 25.

20.

PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.

Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW.

Cancer Res. 2011 Jun 15;71(12):4061-7. doi: 10.1158/0008-5472.CAN-11-0549. Epub 2011 Apr 8.

21.

A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.

Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ, Bell DW.

Clin Cancer Res. 2011 Mar 15;17(6):1331-40. doi: 10.1158/1078-0432.CCR-10-0540. Epub 2011 Jan 25.

22.

Functionally defective germline variants of sialic acid acetylesterase in autoimmunity.

Surolia I, Pirnie SP, Chellappa V, Taylor KN, Cariappa A, Moya J, Liu H, Bell DW, Driscoll DR, Diederichs S, Haider K, Netravali I, Le S, Elia R, Dow E, Lee A, Freudenberg J, De Jager PL, Chretien Y, Varki A, MacDonald ME, Gillis T, Behrens TW, Bloch D, Collier D, Korzenik J, Podolsky DK, Hafler D, Murali M, Sands B, Stone JH, Gregersen PK, Pillai S.

Nature. 2010 Jul 8;466(7303):243-7. doi: 10.1038/nature09115. Epub 2010 Jun 16.

23.

A novel Wilms tumor 1 (WT1) target gene negatively regulates the WNT signaling pathway.

Kim MS, Yoon SK, Bollig F, Kitagaki J, Hur W, Whye NJ, Wu YP, Rivera MN, Park JY, Kim HS, Malik K, Bell DW, Englert C, Perantoni AO, Lee SB.

J Biol Chem. 2010 May 7;285(19):14585-93. doi: 10.1074/jbc.M109.094334. Epub 2010 Mar 10.

24.

Our changing view of the genomic landscape of cancer.

Bell DW.

J Pathol. 2010 Jan;220(2):231-43. doi: 10.1002/path.2645. Review.

25.

Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator Claspin.

Zhang J, Song YH, Brannigan BW, Wahrer DC, Schiripo TA, Harris PL, Haserlat SM, Ulkus LE, Shannon KM, Garber JE, Freedman ML, Henderson BE, Zou L, Sgroi DC, Haber DA, Bell DW.

Mol Cancer Res. 2009 Sep;7(9):1510-6. doi: 10.1158/1541-7786.MCR-09-0033. Epub 2009 Sep 8.

26.

Detection of mutations in EGFR in circulating lung-cancer cells.

Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M, Haber DA.

N Engl J Med. 2008 Jul 24;359(4):366-77. doi: 10.1056/NEJMoa0800668. Epub 2008 Jul 2.

27.

Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms.

Bell DW, Brannigan BW, Matsuo K, Finkelstein DM, Sordella R, Settleman J, Mitsudomi T, Haber DA.

Clin Cancer Res. 2008 Jul 1;14(13):4079-84. doi: 10.1158/1078-0432.CCR-07-5030.

28.

Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias.

Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, Sweetser DA, McClatchey AI, Bernard OA, Look AT, Bell DW, Scadden DT, Haber DA.

Blood. 2008 May 1;111(9):4716-22. doi: 10.1182/blood-2007-10-113068. Epub 2008 Feb 25.

29.

Isolation of rare circulating tumour cells in cancer patients by microchip technology.

Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M.

Nature. 2007 Dec 20;450(7173):1235-9.

30.

Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib.

Zampa G, Moscato M, Brannigan BW, Morabito A, Bell DW, Normanno N.

Lung Cancer. 2008 Jun;60(3):452-4. Epub 2008 Feb 20.

PMID:
18079016
31.

Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.

Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade OI, Le Marchand L, Henderson BE, Altshuler D, Haber DA, Freedman ML.

Int J Cancer. 2007 Dec 15;121(12):2661-7.

32.

Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation.

Godin-Heymann N, Bryant I, Rivera MN, Ulkus L, Bell DW, Riese DJ 2nd, Settleman J, Haber DA.

Cancer Res. 2007 Aug 1;67(15):7319-26.

33.

Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.

Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, Haber DA, Anderson KS, Settleman J.

Cancer Res. 2007 Mar 1;67(5):2325-30.

34.

Epidermal growth factor receptor mutations in lung cancer.

Sharma SV, Bell DW, Settleman J, Haber DA.

Nat Rev Cancer. 2007 Mar;7(3):169-81. Review.

PMID:
17318210
35.

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.

Sequist LV, Bell DW, Lynch TJ, Haber DA.

J Clin Oncol. 2007 Feb 10;25(5):587-95. Review.

PMID:
17290067
36.

A recurrent mutation in PALB2 in Finnish cancer families.

Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, Kallioniemi A, Pylkäs K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R.

Nature. 2007 Mar 15;446(7133):316-9. Epub 2007 Feb 7.

PMID:
17287723
37.

An X chromosome gene, WTX, is commonly inactivated in Wilms tumor.

Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim JC, Feinberg AP, Gerald WL, Vargas SO, Chin L, Iafrate AJ, Bell DW, Haber DA.

Science. 2007 Feb 2;315(5812):642-5. Epub 2007 Jan 4.

38.

Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein.

Hur J, Bell DW, Dean KL, Coser KR, Hilario PC, Okimoto RA, Tobey EM, Smith SL, Isselbacher KJ, Shioda T.

Cancer Res. 2006 Oct 15;66(20):10153-61.

39.

Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.

Haber DA, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, Sharma SV, Lynch TJ, Settleman J.

Cold Spring Harb Symp Quant Biol. 2005;70:419-26. Review.

PMID:
16869779
40.

Epidermal growth factor receptor mutation testing in the care of lung cancer patients.

Sequist LV, Joshi VA, Jänne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4403s-4408s. Review.

41.

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.

Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DW.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4283-7.

42.

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA.

Clin Cancer Res. 2006 Jul 1;12(13):3908-14.

43.

A blood-based test for epidermal growth factor receptor mutations in lung cancer.

Bell DW, Haber DA.

Clin Cancer Res. 2006 Jul 1;12(13):3875-7. Review. No abstract available.

44.

Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis.

Smolen GA, Muir B, Mohapatra G, Barmettler A, Kim WJ, Rivera MN, Haserlat SM, Okimoto RA, Kwak E, Dahiya S, Garber JE, Bell DW, Sgroi DC, Chin L, Deng CX, Haber DA.

Cancer Res. 2006 Apr 1;66(7):3452-5.

45.

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752.

Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, Haber DA.

Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2316-21. Epub 2006 Feb 6.

46.

Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.

Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DW.

Clin Cancer Res. 2005 Nov 15;11(22):8105-8.

47.

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, Haber DA.

Nat Genet. 2005 Dec;37(12):1315-6. Epub 2005 Oct 30.

PMID:
16258541
48.

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA.

J Clin Oncol. 2005 Nov 1;23(31):8081-92. Epub 2005 Oct 3.

PMID:
16204011
49.

MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability.

Niendorf KB, Goggins W, Yang G, Tsai KY, Shennan M, Bell DW, Sober AJ, Hogg D, Tsao H.

J Med Genet. 2006 Jun;43(6):501-6. Epub 2005 Sep 16.

50.

Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer.

Kwak EL, Moberg KH, Wahrer DC, Quinn JE, Gilmore PM, Graham CA, Hariharan IK, Harkin DP, Haber DA, Bell DW.

Gynecol Oncol. 2005 Jul;98(1):124-8.

PMID:
15913747

Supplemental Content

Support Center